Fig. 4.

Treatment with a CXCL1-neutralizing antibody prevents Ang II-induced inflammatory cell infiltration.

(A) WT C57BL/6J mice were pretreated with IgG control or anti-CXCL1 neutralizing antibody (100 μg/mouse/day) and then infused with angiotensin II for three weeks. Flow cytometry analyses of CD45⁺ cells, CD45⁺ CXCR2⁺ cells, CD45⁺ CD11b⁺ F480⁺ CXCR2⁺ macrophages and CD45⁺ CD11b⁺ Gr-1⁺ CXCR2⁺ neutrophils cells in each group (left). The percentage of gated cells among total cells (right, n = 6); (B) Representative images of Iba1 IHC staining in each group, red arrows indicate the Iba1-positive microglia/macrophages(scale bar: 50 μm, left); quantification of positive cells (right; n = 6 per group); (C) qPCR analyses of the mRNA levels of IL-1β, IL-6, tumour necrosis factor-α (TNF-α), and monocyte chemoattractant protein-1 (MCP-1) in each group (n = 6). GAPDH was used as an internal control. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)